The health ministry chief, Mikhail Murashko, affirmed that the production and supply of medicines in Russia remain on track. He stressed that there is no need for residents to stockpile drugs and that pharmaceutical availability continues as usual, a stance he shared during recent briefings and reporting by consolidating outlets including TASS.
In his assessment, the price of essential medicines is held steady by government measures, with adjustments only possible for objectively justified reasons. Murashko underscored that this policy helps ensure that critical medications stay affordable across the entire pharmacy network, from city clinics to rural dispensaries, even amid fluctuating market conditions. The implication is a stable access framework designed to protect the public’s health needs while maintaining supply discipline.
Murashko noted a recent meeting with drug suppliers on a prior Tuesday, where industry representatives indicated that consumer demand is normalizing after fluctuations seen earlier. He observed that current consumption levels are returning to the volumes recorded in March of the previous year, signaling a reversion to established seasonal patterns and demand cycles. This observation aligns with ongoing supply planning and inventory management across distribution channels, including warehouses and retail networks.
Earlier statements from Roszdravnadzor officials highlighted the role of public sentiment in shaping pharmacy stock levels. The agency has emphasized that fretting about shortages often amplifies perceived gaps, prompting unnecessary hoarding. Officials pointed out that there are ample medicines stored in warehouses and urged citizens to avoid artificial scarcity and to resist overbuying, which can disrupt orderly distribution and lead to genuine scarcities later on.
Overall, health authorities are framing the current situation as one of steady access, disciplined pricing, and prudent consumer behavior. The goal is to maintain reliable availability of vital medicines while preventing price volatility that could undermine patient outcomes. Analysts continue to monitor supply chains, regulatory actions, and market dynamics to ensure a resilient pharmaceutical sector that supports public health objectives across the country.